BI 3034701 (C-14)
DrugBI 3034701 mixed with [C-14]BI 3034701
NCT Number: NCT07708493
The main objectives of this trial are:
To assess the mass balance (total recovery of [14C]-radioactivity) in urine, faeces, and expired air after a single subcutaneous dose of BI 3034701 (C-14) in healthy male trial participants.
Trial opening soon.
Get Notified18 year–65 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BI 3034701 mixed with [C-14]BI 3034701
Time frame: Up to Day 50.
Time frame: Up to Day 50.
Time frame: Up to Day 49.
Time frame: Up to Day 50.
Time frame: Up to Day 22.
Time frame: Up to Day 22.
Time frame: Up to Day 22.
Time frame: Up to Day 22.
Contact information is provided by the study sponsor or research team.
Boehringer Ingelheim
Industry
A Phase I, Open-label, Single-dose, Single-arm Trial to Investigate Metabolism and Pharmacokinetics of BI 3034701 (C-14) Administered to (Otherwise) Healthy Male Volunteers With Normal Body Weight or Overweight
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07774325
Healthy
Biberach, Germany
View Trial DetailsNCT07768813
Body Weight, Healthy
Mannheim, Germany
View Trial DetailsNCT07767487
Healthy
Anaheim, California, United States
View Trial DetailsNCT07765199
Arterial Puncture, Cardiovascular Diseases
Orléans, France
View Trial Details